These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10369798)

  • 21. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
    Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB
    Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.
    Olszewski WL; Pazdur J; Kubasiewicz E; Zaleska M; Cooke CJ; Miller NE
    Arthritis Rheum; 2001 Mar; 44(3):541-9. PubMed ID: 11263768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?
    Buch MH; Conaghan PG; Quinn MA; Bingham SJ; Veale D; Emery P
    Ann Rheum Dis; 2004 Oct; 63(10):1344-6. PubMed ID: 15033655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
    Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
    Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
    Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
    Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
    Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
    Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis.
    De Rycke L; Baeten D; Foell D; Kruithof E; Veys EM; Roth J; De Keyser F
    J Pathol; 2005 May; 206(1):17-27. PubMed ID: 15809977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Apperceptive form visual agnosia caused by anti-TNFalpha therapy to rheumatoid arthritis].
    Kobayashi S; Tanno M; Nakamura I; Ito K; Ugawa Y
    Rinsho Shinkeigaku; 2007; 47(2-3):96-9. PubMed ID: 17511276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis.
    Arvidson NG; Larsen A; Aaseth J; Larsson A
    Scand J Clin Lab Invest; 2007; 67(3):337-42. PubMed ID: 17454848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP; Taggart AJ
    Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.